Advances in the treatment of chronic lymphocytic leukemia

Current Oncology Reports

Volumn 7, Issue 5, 2005, Pages 333-338

  Lamanna, Nicole ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALEMTUZUMAB; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CASPASE 3; CD19 ANTIGEN; CD20 ANTIBODY; CD20 ANTIGEN; CD23 ANTIGEN; CD40 LIGAND; CD52 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLIN DEPENDENT KINASE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; FLAVOPIRIDOL; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 12; LUMILIXIMAB; MONOCLONAL ANTIBODY; OBLIMERSEN; PENTOSTATIN; PHOSPHOTRANSFERASE; PREDNISONE; PROTEIN BCL 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC PROPHYLAXIS; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CYTOTOXICITY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG RESPONSE; FEVER; GENE THERAPY; HEALTH CARE AVAILABILITY; HEMOLYTIC ANEMIA; HERPES ZOSTER; HUMAN; HYPERKALEMIA; IMMUNE DEFICIENCY; INFECTION; MONOTHERAPY; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; QUALITY CONTROL; RELIABILITY; REVIEW; THROMBOCYTOPENIA; TREATMENT INDICATION;

EID: 24944445228     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0059-0     Document Type: Review

References (50)

1. Dighiero G, Travade P, Chevret S, et al., and The French Cooperative Group on CLL: B-cell chronic lymphocytic leukemia: present status and future directions. Blood 1991, 78:1901-1914.
2. O'Brien S, del Giglio A, Keating M: Review article: Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995, 85:307-318.
3. Grever MR, Kopecky KJ, Coltman CA, et al.: Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouvelle Revue Francaise D'Hemtologie 1988, 320:457-459.
4. Keating MJ, Kantarjian H, Talpaz et al.: Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989, 74:19-25.
5. Juliusson G, Liliemark J: High complete remission rate from 2-chloro-2′ deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993, 11:679-689.
6. Saven A, Leman RH, Kosty M, et al.: 2-chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995, 13:570-574.
7. Grever MR, Leiby JM, Kraut EH, et al.: Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985, 3:1196-1201.
8. Dillman RO, Mick R, Ross McIntyre OR: Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia Group B. J Clin Oncol 1989, 7:433-438.
9. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825-2833.
10. Nguyen DT, Amess JA, Doughty H, et al.: IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999, 62:76-82.
11. Osterborg A, Dyer MJ, Bunjes D, et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997, 15:1567-1574.
12. Rowan W, Tite J, Topley P, Brett SJ: Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998, 95:427-436.
13. Dighiero G, Maloum K, Desablens B, et al.: Chlorambucin in indolent chronic lymphocytic leukemia. N Engl J Med 1998, 338:1506-1514.
14. Keating MJ, Kantarjian H, O'Brien S, et al.: Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 1991, 9:44-49.
15. Rai KR, Peterson BL, Appelbaum FR, et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750-1757.
16. Robertson LE, Huh YO, Butler JJ, et al.: Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: Clinical, immunophenotypic, and molecular analysis. Blood 1992, 80:29-36.
17. Weiss M, Glenn M, Maslak P, et al.: Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia 2000, 14:557-582.
18. O'Brien S, Kantarjian H, Beran M, et al.: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993, 82:1695-1700.
19. Elias L, Stock-Novack D, Head DR, et al.: A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group study. Leukemia 1993, 7:361-365.
20. Weiss M, Spiess T, Berman E, Kempin S: Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 1994, 8:1290-1293.
21. O'Brien S, Kantarjian HM, Cortes MC, et al.: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:1414-1420.
22. Wierda W, O'Brien S, Wen S, et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin J Clin Oncol 2005, 23:4070-4078.
23. Keating MJ, O'Brien S, Albitar M, et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4079-4088.
24. Flinn IW, Byrd JC, Morrison C, et al.: Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood 2000, 96:71-75.
25. Lamanna N, Weiss MA, Maslak PG, et al.: Sequential therapy with fludarabine, high dose cyclophosphamide, and rituximab induces a high incidence of complete response in patients with chronic lymphocytic leukemia. Blood 2003, 102:1603a.
26. Robak T, Blonski J, Kasznicki M, et al.: Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000, 96:2723-2729.
27. Weiss MA, Maslak PG, Jurcic JG, et al.: Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003, 21:1278-1284.
28. Lamanna N, Kalycio M, Maslak P, et al.: Pentostatin and cyclophosphamide with or without rituximab has significant activity in patients with previously treated chronic lymphocytic leukemia and other low grade lymphoid neoplasms. Blood 2004, 104:3484a.
29. Kay NE, Geyer SM, Lin T, et al.: Combination chemotherapy with pentostatin, cyclophosphamide, and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated B-chronic lymphocytic leukemia. Blood 2004, 104:339a.
30. Foran JM, Rohatiner AZS, Cunningham D, et al.: European phase II study of rituximab (chimeric anti-CD 20 monoclonal antibody for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18:317-324.
31. Huhn D, von Schilling C, Wilhelm M, et al.: Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001, 98:1326-1331.
32. Itala M, Geisler CH, Kimby E, et al.: Standard-dose anti-CD20 antibody rituximab, has efficacy in chronic lymphocytic leukemia: results from a Nordic multicentre study. Eur J Haematol 2002, 69:129-134.
33. Piro LD, White CA, Grillo-Lopez AJ, et al.: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999, 10:655-661.
34. O'Brien SM, Kantarjian H, Thomas DA, et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:2165-2170.
35. Byrd JD, Murphy T, Howard RS, et al.: Rituximab, using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001, 19:2153-2164.
36. Hainsworth JD, Litchy S, Barton JH, et al.: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2002, 21:1746-1751.
37. Byrd JC, Peterson BL, Morrison VA, et al.: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab, in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003, 101:6-14.
38. Keating MJ, Flinn I, Jain V, et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who failed fludarabine: results of a large international study. Blood 2002, 99:3554-3561.
39. Lundin J, Kimby E, Bjorkholm M, et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002, 100:768-773.
40. O'Brien S, Kantarjian HM, Thomas DA, et al.: Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003, 98:2657-2663.
41. Rai K, Byrd J, Peterson BL, Larson RA: A phase II trial of fludarabine followed by alemtuzumab (Campath-1H) in previously untreated chronic lymphocytic leukemia patients with active disease: Cancer and Leukemia Group B (CALGB) Study 19901. Blood 2002, 100:205a.
42. Faderl S, Thomas DA, O'Brien S, et al.: Experience with alemtuzumab plus rituximab, in patients with relapsed and refractory lymphoid malignancies. Blood 2003, 101:3413-3415.
43. Konig A, Schwartz GK, Mohammad RM, Al-Katib A, Gabrilove JL: The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-d and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood 1997, 90:4307-4312.
44. Byrd JC, Shinn C, Waselenko JK, et al.: Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-3 modulation or dependent on functional p53. Blood 1997, 92:3804-3816.
45. Byrd JC, Lin TS, Dalton JT, et al.: Flavopiridol administered as a pharmacologically-derived schedule demonstrates marked clinical activity in refractory, genetically high risk, chronic lymphocytic leukemia (CLL). Blood 2004, 104:341a.
46. Byrd JC, O'Brien S, Flinn I, et al.: Interim results from a phase I study of lumiliximab, (IDEC-152, anti-CD23 antibody) therapy for relapsed or refractory CLL. Blood 2003, 102:248a.
47. Rai KR, O'Brien S, Cunningham C, et al.: Genasense (Bcl-2 Antisense) monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia: phase 1 and 2 results. Blood 2002, 20:1490a.
48. Rai KR, Moore JO, Boyd TE, et al.: Phase 3 randomized trial of fludarabine/cyclophosphamide chemotherapy with or without oblimersen sodium (Bcl-2 antisense, Genasense, G3139) for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Blood 2004, 104:338a.
49. Wierda WG, Cantwell MJ, Woods SJ, et al.: CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 2000, 96:2917-2924.
50. Brentjens RJ, Latouche JB, Santos E, et al.: Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD-80 and interleukin-15. Nat Med 2003, 9:279-286.